Quadruple Therapy Offers High SVR Rates in Patients with HCV Genotype 4 with Previous Treatment Failure

Table 2

Baseline and follow-up laboratory investigations of the studied group (n = 103).

Variable:	Pretreatment mean ± SD	W4 mean ± SD	W8 mean ± SD	W12	W12 post	value
Serum creatinine	0.89 ± 0.25	0.89 ± 0.23	0.93 ± 0.26	0.90 ± 0.14	0.90 ± 0.11	0.43
WBCs	6613.0 ± 2298.8	6756.00 ± 2244.51	6721.0 ± 2046.3	6626.5 ± 1909.9	6632.0 ± 1857.3	0.625
HB	13.65 ± 1.70	13.11 ± 1.59	12.16 ± 1.76	12.12 ± 1.88	12.90 ± 1.18	<0.001
Plt	152.51 ± 47.69	160.78 ± 65.09	154.10 ± 56.17	163.07 ± 55.88	161.25 ± 52.04	0.580
ALT	53.39 ± 35.28	27.71 ± 13.28	24.77 ± 10.60	24.85 ± 6.87	24.59 ± 5.89	<0.001
AST	51.55 ± 37.35	28.83 ± 14.28	25.24 ± 9.36	26.07 ± 6.18	25.82 ± 5.38	<0.001
Total bilirubin	1.10 ± 0.45	1.24 ± 0.70	1.16 ± 0.61	1.21 ± 0.51	1.13 ± 0.37	0.104